Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Fiscal Q3 Sales Up 20 Percent; R&D Spending Rises Nearly 80 Percent

This article has been updated from a previous version, which miscalculated the company's R&D spending.
NEW YORK (GenomeWeb News) — Clinical Data’s fiscal third-quarter revenues increased 20 percent as R&D spending rose by nearly 80 percent and net losses decreased 580 percent, according to preliminary earnings report.
Total receipts for the three months ended Dec. 31, 2006, increased to $22 million from $18.4 million year over year.
CEO Drew Fromkin said the company has “begun to grow revenues in our genomics business,” and said it opened "important distribution channels in Europe and elsewhere" through agreements with several companies.  
R&D spending for the third quarter rose to $4.5 million from $2.5 million in the same quarter last year.
The company said net loss decreased to $6.3 million from $42.8 million in the year-ago period.
Looking forward, Fromkin said the company plans to push its Phase III trial for the antidepressant drug vilazodone, which last year Clinical Data said it will spin out into a separate business.
The company did not list its balance sheet for the quarter.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.